Pharmacogenetics
Our multiplex PCR and mass spectrometry pharmacogenetics assay can detect single nucleotide polymorphisms, internal deletion variants, and copy number variants for several genes with pharmacogenetic implications.
This type of testing is performed to aid in a healthcare provider’s determination of effective drug therapies and reduce the patient’s risk of adverse effects. Based on a patient’s genetic makeup, their test results will outline how their DNA will affect drug metabolism.
Additionally, our report includes a summary of patient-specific indications of drug-to-drug interaction to further optimize medication therapies.
Specimen requirements: A buccal (cheek) swab provided by Genesys Diagnostics (OraCollect Dx; DNA Genotek Buccal Swab), or a whole blood sample (~5 mL) in a lavender top (K2EDTA) collection tube.
ADHD/Neurology Panel: Antiaddictives, anti-ADHD agents, antidepressants, anticonvulsants, antidementia agents, antipsychotics, benzodiazepines and other neurological agents
Genes: COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, OPRM1
Cardiology Panel: Angiotensin II receptor antagonists, antianginal agents, antiarrhythmics, anticoagulants, antiplatelets, beta-blockers, diuretics, statins and others
Genes: APOE, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR, SLCO1B1, VKORC1
Gastrointestinal Panel: Antiemetics, proton-pump inhibitors
Genes: ABCB1, CYP2C19, CYP2C9, CYP2D6, CYP3A4
Mental Health/Psychiatry Panel: Antiaddictives, anti-ADHD agents, antidepressants, anticonvulsants, antidementia agents, anti-psychotics, benzodiazepines
Genes: ANKK1/DRD2, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, MTHFR
Orthopedic Panel: Anti-hyperuricemias and anti-gout agents, immunomodulators
Genes: ABCB1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR, OPRM1, VKORC1
Pain Management Panel: Fibromyalgia agents, muscle relaxants, NSAIDs, opioids
Genes: COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR, OPRM1
Urological Panel: 5 alpha reductase inhibitors and alpha-blockers for benign prostatic hyperplasia, antispasmodics for overactive bladder, phosphodiesterase inhibitors for erectile dysfunction
Comprehensive Panel: All of the above
Genes: ABCB1, APOE, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DRD2, Factor II, Factor V, GLP1R, MTHFR, OPRM1, PNPLA5, SLCO1B1, SULT4A1, VKORC1
Pharmacogenetics Panels:
Click each gene for more information
Turnaround time: 5-7 business days
Say goodbye to the guesswork
By understanding an individual's unique genetic makeup, pharmacogenetic testing can provide personalized healthcare that is tailored to each patient's specific needs.
Limitations: This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Absence of a detectable gene mutation does not rule out the possibility that a patient has different phenotypes due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities and lifestyle habits. Technical limitations include the possibility of laboratory error and inaccuracy of the test due to unknown rare variants.
